How Melatonin Signals Darkness to the Suprachiasmatic Nucleus and Why Its Legal Status Varies Globally

On December 12, 2013, the US Food and Drug Administration issued a scientific memorandum evaluating the safety and regulatory status of melatonin. This document cemented the hormone's position in the United States as a dietary supplement, allowing it to be sold over the counter without pre-market pharmaceutical approval.[5]

Yet across the Atlantic, the European Medicines Agency treats the exact same molecule fundamentally differently. On July 26, 2018, the EMA updated its authorization for Circadin, a 2-milligram prolonged-release melatonin formulation, maintaining its strict classification as a prescription-only medicine for patients over 55 suffering from primary insomnia.[6]

This stark regulatory divergence highlights a global paradox. The biological mechanism by which melatonin operates is universally recognized by chronobiologists, yet the legal frameworks governing its use remain deeply fractured.[8]

To understand this divide, one must look at how the hormone actually functions in the human brain. Melatonin is synthesized by the pineal gland, a small endocrine structure located deep within the brain, in direct response to fading light levels detected by the retina.[1]

The primary target for this chemical signal is the suprachiasmatic nucleus (SCN), a tiny cluster of roughly 20,000 neurons situated in the hypothalamus. The SCN acts as the body's master circadian clock, orchestrating the physiological timing of everything from core temperature to hormone release.[2]

Melatonin does not forcibly induce sleep in the manner of a traditional sedative or benzodiazepine. Instead, it signals the biological onset of darkness, effectively telling the SCN that the environmental night has arrived.[7]

This signaling is achieved through two specific G-protein coupled receptors, designated MT1 and MT2, which are densely expressed on the surface of SCN neurons.[2]

The MT1 receptor is primarily responsible for attenuating the SCN's wake-promoting signal. When melatonin binds to MT1, it suppresses neuronal firing in the master clock, dampening the brain's alertness and facilitating the transition into sleep.[7]

Conversely, the MT2 receptor is involved in phase-shifting the circadian rhythm. Activation of MT2 by melatonin helps to entrain, or synchronize, the internal biological clock to the external 24-hour light-dark cycle, which is why the hormone is frequently used to combat jet lag.[2]

"Melatonin and its receptors represent a new class of sleep-promoting agents," researchers noted in the Journal of Clinical Sleep Medicine, emphasizing that the hormone works by modulating the circadian drive for wakefulness rather than broadly depressing the central nervous system.[7]

Beyond the suprachiasmatic nucleus, melatonin exerts systemic effects throughout the body. A comprehensive review published in the journal Molecules detailed the chronobiology of melatonin outside the SCN, highlighting its potent antioxidant properties and its role in modulating immune function.[3]

The widespread distribution of melatonin receptors in peripheral tissues—including the cardiovascular system, the gastrointestinal tract, and the liver—suggests that the hormone's daily rhythm helps synchronize peripheral clocks with the master SCN clock.[3]

Despite this clear biological consensus, the National Center for Complementary and Integrative Health (NCCIH) warns that the US regulatory framework for dietary supplements creates significant variability for consumers. Because the FDA does not evaluate supplements for efficacy before they hit the market, commercial melatonin products can vary widely in their actual hormone content.[4]

The NCCIH points to studies indicating that some over-the-counter melatonin supplements contain significantly more or less of the active ingredient than listed on the label, and in some cases, have been found to contain unlisted compounds like serotonin.[4]

This variability is precisely why European regulators have taken a more restrictive approach. By classifying the 2-milligram prolonged-release formulation as a prescription medicine, the EMA ensures that the product meets stringent pharmaceutical standards for manufacturing, purity, and dosage consistency.[6]

The FDA's 2013 memorandum, meanwhile, focused primarily on the lack of severe adverse events reported in the literature, concluding that the available data did not warrant reclassifying the hormone as a controlled drug in the US market.[5]

For the average consumer, this means that accessing a biologically identical molecule requires a doctor's visit in London or Berlin, but only a trip to the local grocery store in New York or Los Angeles.[8]

As research continues to uncover the nuanced roles of the MT1 and MT2 receptors, the debate over melatonin's legal status is likely to persist. The challenge for future regulators will be balancing the hormone's proven safety profile with the need for reliable, accurately dosed formulations.[8]